Research programme: oncolytic virus cancer therapeutics - DNAtrix

Drug Profile

Research programme: oncolytic virus cancer therapeutics - DNAtrix

Alternative Names: Delta 24 ACT; Delta-24-RGDOX; DNX-2440; DNX-2450; MYX-135

Latest Information Update: 20 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DNAtrix
  • Class Oncolytic viruses
  • Mechanism of Action Cell death stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Solid tumours
  • Research Haematological malignancies

Most Recent Events

  • 13 Nov 2017 Preclinical trials in Cancer in USA (Parenteral)
  • 13 Nov 2017 DNAtrix plans a clinical trial of DNX 2440 for solid tumours
  • 08 Nov 2016 DNAtrix in-licenses myxoma oncolytic virus platform from University of Florida
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top